1. Investigating the relationship between thalamic iron concentration and disease severity in secondary progressive multiple sclerosis using quantitative susceptibility mapping: Cross-sectional analysis from the MS-STAT2 randomised controlled trial
- Author
-
Thomas Williams, Nevin John, Alberto Calvi, Alessia Bianchi, Floriana De Angelis, Anisha Doshi, Sarah Wright, Madiha Shatila, Marios C. Yiannakas, Fatima Chowdhury, Jon Stutters, Antonio Ricciardi, Ferran Prados, David MacManus, Francesco Grussu, Anita Karsa, Becky Samson, Marco Battiston, Claudia A.M. Gandini Wheeler-Kingshott, Karin Shmueli, Olga Ciccarelli, Frederik Barkhof, Jeremy Chataway, Wallace Brownlee, Claudia AM. Gandini Wheeler-Kingshott, Jonathan Stutters, Ferran Prados Carrasco, Marios Yiannakas, Megan Wynne, Marie Braisher, James Blackstone, Leanne Hockey, Josephine Parker, Jennifer Flight, Chris Frost, Jennifer Nicholas, Stuart Nixon, and Judy Beveridge
- Subjects
Multiple sclerosis ,Deep grey matter ,Thalamus ,Iron ,Quantitative susceptibility mapping ,Neurosciences. Biological psychiatry. Neuropsychiatry ,RC321-571 - Abstract
Background: Deep grey matter pathology is a key driver of disability worsening in people with multiple sclerosis. Quantitative susceptibility mapping (QSM) is an advanced magnetic resonance imaging (MRI) technique which quantifies local magnetic susceptibility from variations in phase produced by changes in the local magnetic field. In the deep grey matter, susceptibility has previously been validated against tissue iron concentration. However, it currently remains unknown whether susceptibility is abnormal in older progressive MS cohorts, and whether it correlates with disability. Objectives: To investigate differences in mean regional susceptibility in deep grey matter between people with secondary progressive multiple sclerosis (SPMS) and healthy controls; to examine in patients the relationships between deep grey matter susceptibility and clinical and imaging measures of disease severity. Methods: Baseline data from a subgroup of the MS-STAT2 trial (simvastatin vs. placebo in SPMS, NCT03387670) were included. The subgroup underwent clinical assessments and an advanced MRI protocol at 3T. A cohort of age-matched healthy controls underwent the same MRI protocol. Susceptibility maps were reconstructed using a robust QSM pipeline from multi-echo 3D gradient-echo sequence. Regions of interest (ROIs) in the thalamus, globus pallidus and putamen were segmented from 3D T1-weighted images, and lesions segmented from 3D fluid-attenuated inversion recovery images. Linear regression was used to compare susceptibility from ROIs between patients and controls, adjusting for age and sex. Where significant differences were found, we further examined the associations between ROI susceptibility and clinical and imaging measures of MS severity. Results: 149 SPMS (77% female; mean age: 53 yrs; median Expanded Disability Status Scale (EDSS): 6.0 [interquartile range 4.5–6.0]) and 33 controls (52% female, mean age: 57) were included.Thalamic susceptibility was significantly lower in SPMS compared to controls: mean (SD) 28.6 (12.8) parts per billion (ppb) in SPMS vs. 39.2 (12.7) ppb in controls; regression coefficient: −12.0 [95% confidence interval: −17.0 to −7.1], p
- Published
- 2024
- Full Text
- View/download PDF